KR960021018A - 약제학적 조성물 - Google Patents

약제학적 조성물 Download PDF

Info

Publication number
KR960021018A
KR960021018A KR1019940033397A KR19940033397A KR960021018A KR 960021018 A KR960021018 A KR 960021018A KR 1019940033397 A KR1019940033397 A KR 1019940033397A KR 19940033397 A KR19940033397 A KR 19940033397A KR 960021018 A KR960021018 A KR 960021018A
Authority
KR
South Korea
Prior art keywords
composition
staurosporin
active ingredient
esters
glycol
Prior art date
Application number
KR1019940033397A
Other languages
English (en)
Other versions
KR100366176B1 (ko
Inventor
린드세이 알렌 헨리 로이
폴 매튜즈 그레함
Original Assignee
베르너 발데그
시바-가이기 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데그, 시바-가이기 에이지 filed Critical 베르너 발데그
Publication of KR960021018A publication Critical patent/KR960021018A/ko
Application granted granted Critical
Publication of KR100366176B1 publication Critical patent/KR100366176B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 C8-C18포화 지방산의 글리세롤과의 에스테르와 폴리에틸렌 글리콜과의 에스테르의 혼합물과 같은 포화 폴리알킬렌 글리콜 글리세라이드중의 스타우로스포린 활성 성분의 용액 또는 분산액을 포함하는 약제학적 조성물에 관한 것이다. 당해 조성물은 캡슐제로 또는 수성 매질중의 분산제로서 투여할 수 있다.

Description

약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 포화 폴리알킬렌 글리콜 글리세라이드중의 스타우로스포린 활성 성분의 용액 또는 분산액을 포함하는 약제학적 조성물.
  2. 제1항에 있어서, 스타우로스포린 활성 성분이 N-벤조일 스타우로스포린인 조성물.
  3. 제1항 또는 제2항에 있어서, 글리콜 글리세라이드가 하나 이상의 C8-C18포화 지방산의 글리세릴 에스테르와 폴리에틸렌 글리콜 에스테르의 혼합물인 조성물.
  4. 제3항에 있어서, 글리콜 글리세라이드가 하나 이상의 C8-C18포화 지방산의 글리세롤과의 에스테르 분자량이 1,000 내지 2,000인 폴리에틸렌 글리콜과의 에스테르의 혼합물인 조성물.
  5. 제4항에 있어서, 폴리에틸렌 글리콜의 분자량이 1,400 내지 1,600인 조성물.
  6. 제1항 내지 제5항중의 어느 한 항에 있어서, 스타우로스포린 활성 성분이 조성물의 1 내지 30중량%의 양으로 존재하는 조성물.
  7. 제6항에 있어서, 스타우로스포린 활성 성분이 조성물의 10 내지 20중량%의 양으로 존재하는 조성물.
  8. 캡슐제에 함유된 제1항 내지 제7항중의 어느 한 항에 따른 조성물.
  9. 수성 매질중의 분산액으로서의 제1항 내지 제7항중의 어느 한 항에 따른 조성물.
  10. 제9항에 있어서, 분산액이 조성물을 0.5 내지 70중량% 함유하는 조성물.
  11. 제3항 내지 제5항중의 어느 한 항에 명시된 포화 폴리알킬렌 글리콜 글리세라이드를 용융시키고, 제1항 또는 제2항에 명시된 스타우로스포린 활성 성분을 용융된 글리세라이드와 혼합한 다음 생성된 혼합물을 고형화시킴을 포함하여, 약제학적 조성물을 제조하는 방법.
  12. 제11항에 있어서, 스타우로스포린 활성 성분이 제6항 또는 제7항에 명시된 양으로 사용되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940033397A 1993-12-11 1994-12-09 스타우로스포린을함유하는약제학적조성물 KR100366176B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9325395.3 1993-12-11
GB939325395A GB9325395D0 (en) 1993-12-11 1993-12-11 Compositions

Publications (2)

Publication Number Publication Date
KR960021018A true KR960021018A (ko) 1996-07-18
KR100366176B1 KR100366176B1 (ko) 2003-03-03

Family

ID=10746475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940033397A KR100366176B1 (ko) 1993-12-11 1994-12-09 스타우로스포린을함유하는약제학적조성물

Country Status (17)

Country Link
US (1) US5736542A (ko)
EP (1) EP0657164B1 (ko)
JP (1) JPH07196512A (ko)
KR (1) KR100366176B1 (ko)
AT (1) ATE185970T1 (ko)
AU (1) AU692801B2 (ko)
CA (1) CA2137764C (ko)
DE (1) DE69421366T2 (ko)
DK (1) DK0657164T3 (ko)
ES (1) ES2140512T3 (ko)
GB (1) GB9325395D0 (ko)
GR (1) GR3032368T3 (ko)
IL (1) IL111872A (ko)
NZ (1) NZ270109A (ko)
PH (1) PH31454A (ko)
PT (1) PT657164E (ko)
ZA (1) ZA949824B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
CA2379035A1 (en) 1999-07-13 2001-01-18 Shiro Akinaga Staurosporin derivatives
DE10042137A1 (de) * 2000-08-28 2002-03-14 Florian Lang sgk2 und sgk3 als diagnostische und therapeutische Targets
PT1372611E (pt) * 2001-03-26 2006-08-31 Novartis Ag Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua
AU2003215623B2 (en) * 2003-03-03 2009-10-22 Florian Lang Sgk1 as diagnostic and therapeutic target
US20040246627A1 (en) * 2003-06-06 2004-12-09 Durrum Thomas M. Disc drive pivot bearing assembly
CA2533861A1 (en) 2003-08-08 2005-02-17 Novartis Ag Combinations comprising staurosporines
US7635675B2 (en) 2003-08-13 2009-12-22 Biocon Limited Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
WO2006082448A1 (en) * 2005-02-07 2006-08-10 Topotarget Uk Limited Assays for agents with selective cytotoxicty to hdac resistant cell lines
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
US20100168219A1 (en) * 2008-12-31 2010-07-01 Jonathan Steven Alexander Chronic inflammation and transplantation
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
EP2925314B1 (en) 2012-11-28 2020-04-01 Aphios Corporation Combination therapeutics and methods for the treatment of neurodegenerative and other diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60185719A (ja) * 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
JPH0699311B2 (ja) * 1986-11-06 1994-12-07 旭化成工業株式会社 抗血管レン縮剤および血管弛緩剤
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
JPH01143877A (ja) * 1987-11-30 1989-06-06 Asahi Chem Ind Co Ltd スタウロスポリン誘導体
EP0383919A4 (en) * 1988-02-04 1992-08-05 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
JPH06501024A (ja) * 1991-03-29 1994-01-27 アメリカ合衆国 皮膚腫瘍形成を予防し、存在する腫瘍の後退の原因になるための医薬組成物と方法
JPH0597708A (ja) * 1991-10-02 1993-04-20 Lion Corp 歯周病治療剤
AU2866992A (en) * 1991-10-10 1993-05-03 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤

Also Published As

Publication number Publication date
EP0657164A1 (en) 1995-06-14
PT657164E (pt) 2000-04-28
US5736542A (en) 1998-04-07
KR100366176B1 (ko) 2003-03-03
DE69421366T2 (de) 2000-03-23
JPH07196512A (ja) 1995-08-01
GB9325395D0 (en) 1994-02-16
IL111872A0 (en) 1995-06-29
NZ270109A (en) 1996-11-26
PH31454A (en) 1998-11-03
IL111872A (en) 1998-02-08
EP0657164B1 (en) 1999-10-27
GR3032368T3 (en) 2000-04-27
CA2137764C (en) 2006-02-07
DE69421366D1 (de) 1999-12-02
DK0657164T3 (da) 2000-04-17
ES2140512T3 (es) 2000-03-01
CA2137764A1 (en) 1995-06-12
AU8030894A (en) 1995-06-22
AU692801B2 (en) 1998-06-18
ZA949824B (en) 1995-07-13
ATE185970T1 (de) 1999-11-15

Similar Documents

Publication Publication Date Title
KR960021018A (ko) 약제학적 조성물
ES2529167T3 (es) Método para utilizar lípidos neutros para modificar la liberación in vivo desde liposomas multivesiculares
DE69230254D1 (de) Herstellung von Mikropartikeln
IL127582A (en) Perfume concentrate and paraffin-based object containing it
HUP9900925A2 (hu) Napfényt szűrő készítmények
EA200300634A1 (ru) Фармацевтическая композиция, содержащая действующее вещество, диспергированное в матрице
ES2105704T3 (es) Composiciones antitranspirantes en barra que presentan propiedades mejoradas de eliminacion por lavado.
DK0786986T3 (da) Anvendelse af en umættet fedtalkohol
LV11884A (lv) Ciklosporina oralas arstnieciskas formas ar augstu biopieejamibu
DE69112914D1 (de) Herstellungsverfahren von Mikrokugeln.
KR880005871A (ko) 초콜렛첨가물, 초콜렛 및 초콜렛의 제조방법
HUP9903855A2 (hu) Orális adagolásra való valproesavat tartalmazó gyógyszerészeti mikrogömbök
KR880007069A (ko) 트리글리세라이드 조성물
JPS55139313A (en) Gel cream composition comprising higher fatty acid ethanol amide, and drug containing it
ATE306907T1 (de) Pharmazeutische zusammensetzung enthaltend estradiol oder ethniylestradiol mit einem extrusionszusatzstoff
JPS56166108A (en) Base for cosmetic and medicine
JPS565436A (en) Preparation of carboxylic acid ester
KR910012222A (ko) 화장비누 조성물
KR910006439A (ko) 열용융형 접착제 조성물
KR960021129A (ko) 오일이 포함된 투명한 겔
KR960000246A (ko) 사이클로스포린 함유 액제 조성물
KR830003908A (ko) 코티코스테로이드 물질을 함유하는 약학조성물

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20111122

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20121123

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee